Online inquiry

IVTScrip™ mRNA-Anti-FCGRT, ARGX-113(Cap 0, 5-Methyl-CTP, 30 nt-poly(A))   (CAT#: GTTS-WQ3249MR)

This product GTTS-WQ3249MR is a type of mRNA having 30 nt poly(A) tail and modified with Cap 0 & 5-Methyl-CTP. It ecodes the monoclonal antibody that targets FCGRT gene. The antibody can be applied in Myasthenia Gravis (MG) research.
Specifications
Product type mRNA
Modified bases 5-Methyl-CTP
5' Cap Cap 0
Species Homo sapiens
RefSeq NM_000484.4
Applications Gene therapy research
Format Powder
Quantity 100 µg
Purification oligo-dT affinity purification
Target Gene
Gene ID 351
UniProt ID P05067
Download
Download resources about mRNA therapeutics development to boost your research.
CUSTOMER REVIEWS and Q&As

There are currently no Customer reviews or questions for IVTScrip™ mRNA-Anti-FCGRT, ARGX-113(Cap 0, 5-Methyl-CTP, 30 nt-poly(A)) (GTTS-WQ3249MR). Click the button above to contact us or submit your feedback about this product.
See other products
CAT Product Name Product Type CDs
GTTS-WQ7645MR IVTScrip™ mRNA-Anti-TNFRSF10B, GEN-1029(Cap 0, 5-Methyl-CTP & Pseudo-UTP, 30 nt-poly(A)) mRNA GEN-1029
GTTS-WQ6735MR IVTScrip™ mRNA-Anti-EGFR, DS 992(Cap 0, N1-Methylpseudo-UTP, 120 nt-poly(A)) mRNA DS 992
GTTS-WQ6116MR IVTScrip™ mRNA-Anti-IL6, COR-001(Cap 1, 5-Methoxy-UTP, 120 nt-poly(A)) mRNA COR-001
GTTS-WQ7064MR IVTScrip™ mRNA-Anti-VEGFA, Fab-12 variant Y0317(Cap 1, 5-Methyl-CTP, 120 nt-poly(A)) mRNA Fab-12 variant Y0317
GTTS-WQ15037MR IVTScrip™ mRNA-Anti-CD47, SRF-231(Cap 0, 5-Methyl-CTP & Pseudo-UTP, 30 nt-poly(A)) mRNA SRF-231
GTTS-WQ10657MR IVTScrip™ mRNA-Anti-S, LY-3819253(Cap 0, 5-Methoxy-UTP, 30 nt-poly(A)) mRNA LY-3819253
GTTS-WQ7623MR IVTScrip™ mRNA-Anti-TNFRSF10B, GEN1029(Cap 0, N1-Methylpseudo-UTP, 120 nt-poly(A)) mRNA GEN1029
GTTS-WQ3915MR IVTScrip™ mRNA-Anti-CD274, BCD-135(Cap 0, 2-Thio-UTP, 120 nt-poly(A)) mRNA BCD-135
All products and services are For Research Use Only and CANNOT be used in the treatment or diagnosis of disease.
webinar

EABR Nanoparticles as a Platform Technology for Hybrid mRNA Vaccine Development

November 20th, 2024, 2 PM–3 PM EST

REGISTER NOW